stockrow
Friday 6 November 2026
Export SRRK’s income statement to Excel — free account
Scholar Rock Holding Corporation
SRRK Healthcare Biotechnology
Scholar Rock Holding Corporation’s revenue for fiscal 2022 (year ended December 2022) was $33.2 million.
- EPS
- +14.3%
- Free cash flow
- +8.88%
- Total debt
- +294.3%
Quarter to June 2026, against a year earlier
46.94
1.44
+3.16%
Follow SRRK
Alert me
Scholar Rock Holding Corporation (SRRK) Revenue
Scholar Rock Holding Corporation's revenue for fiscal 2022 was $33.2M, up 76.4% from $18.8M in fiscal 2021. Over the past ten years it has ranged from $379.0K (fiscal 2016) to $33.2M (fiscal 2022) — the current reading is the highest in ten years. Scholar Rock Holding Corporation ranks 132nd of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2022 | $33.2M | 76.41% |
| FY2021 | $18.8M | 22.16% |
| FY2020 | $15.4M | (24.83%) |
| FY2019 | $20.5M | 5,306.86% |
| FY2016 | $379.0K | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Mar 2022 | $33.2M | 719.78% |
| Dec 2021 | $4.0M | (25.90%) |
| Sep 2021 | $5.5M | 18.91% |
| Jun 2021 | $4.6M | (2.40%) |
| 9 more quarters | Free account |
Against its own ten years
Low $379.0K
High $33.2M
Ten-year median
$18.8M
Current reading's percentile
100
Revenue against peers
| Company | Revenue |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $1.2B |
| SRRK Scholar Rock Holding Corporation | $47.3M |
| COGT Cogent Biosciences, Inc. compare | $23.2M |
| CGON CG Oncology, Inc. compare | $6.2M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| ERAS Erasca, Inc. compare | — |
| MANE Veradermics Incorporated compare | — |
| IMVT Immunovant, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on SRRK
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement